Erratum: Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers (British Journal of Pharmacology (2007) 151, (1061-1070) DOI: 10.1038/sj.bjp.0707303);Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers

British Journal of Pharmacology

Volumn 151, Issue 7, 2007, Pages 1061-1070

  Bingham, B ^a   Jones, P G ^a,b   Uveges, A J ^a   Kotnis, S ^a   Lu, P ^a   Smith, V A ^a   Sun, S C ^a   Resnick, L ^a   Chlenov, M ^a   He, Y ^a   Strassle, B W ^a   Cummons, T A ^a   Piesla, M J ^a   Harrison, J E ^a   Whiteside, G T ^a   Kennedy, J D ^a  

^a PFIZER INC   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

AM1241; Cannabinoid; Enantiomer; Protean agonism

Indexed keywords

3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; CANNABINOID RECEPTOR; CARRAGEENAN; CYCLIC AMP; LIGAND; PHENYLQUINONE;

ANALGESIA; ANIMAL CELL; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CELL LINE; CELL MEMBRANE; CONTROLLED STUDY; DRUG EFFECT; ENANTIOMER; FEMALE; FUNCTIONAL ASSESSMENT; INFLAMMATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACEMIC MIXTURE; RAT; SPECIES DIFFERENCE; VISCERAL PAIN;

EID: 34547578961     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707378     Document Type: Erratum

References (45)

1. Baker D, Pryce G, Davies WL, Hiley CR (2006). In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27: 1-4.
2. 2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 26: 1530-1538.
3. 2 cannabinoid receptor. Biochim Biophys Acta 1576: 255-264.
4. Cabral GA, Marciano-Cabral F (2005). Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J Leukoc Biol 78: 1192-1197.
5. Cascio MG, Bisogno T, Palazzo E, Thomas A, van der Stelt M, Brizzi A et al. (2006). In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands. Br J Pharmacol 149: 431-440.
6. 2 cannabinoid receptors are implicated in inflammatory pain. Pain 96: 253-260.
7. D'Amour FE, Smith D (1941). A method for determining loss of pain sensation. J Pharmacol Exp Ther 72: 74-79.
8. 2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain 118: 327-335.
9. Flygare J, Gustafsson K, Kimby E, Christensson B, Sander B (2005). Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Letters 579: 6885-6889.
10. 1 receptor knockout mice: evidence for a "CB3" receptor. Eur J Pharmacol 461: 27-34.
11. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR et al. (2003). Gaussian Revision B.03. Pittsburgh, PA: Gaussian, Inc.
12. Griffin G, Tao Q, Abood ME (2000). Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther 292: 886-894.
13. Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88.
14. 2 receptor-induced apoptosis of human leukaemia cells. FEBS Lett 579: 5084-5088.
15. 2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 308: 446-453.
16. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ (2004). Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47: 345-358.
17. 2 cannabinoid activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 102: 3093-3098.
18. 2 cannabinoid receptor mediation of antinociception. Pain 122: 36-42.
19. 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529-10533.
20. 2 receptor. J Pharmacol Exp Ther 296: 420-425.
21. Kenakin T (2001). Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15: 598-611.
22. 2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol 542: 100-105.
23. 2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur J Pharmacol 527: 172-174.
24. Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT et al. (2006). A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 316: 780-788.
25. Makriyannis A (2002). University of Connecticut, Receptor selective cannabimimetic aminoalkylindoles. WO 02060447 A1.
26. 2 cannabinoid receptor-mediated peripheral antinociception. Pain 93: 239-245.
27. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
28. 2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absense and presence of inflammation. J Neurophysiol 92: 3562-3574.
29. Nackley AG, Makriyannis A, Hohmann AG (2003). Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 119: 747-757.
30. 2, regulates bone mass. Proc Natl Acad Sci USA 103: 696-701.
31. 2 receptors. Pharmacol Ther 74: 129-180.
32. 2 cannabinoid receptors. Anesthesiology 99: 955-960.
33. 2 cannabinoid receptor. J Vet Sci 3: 179-184.
34. 2 cannabinoid receptor. J Pharmacol Exp Ther 284: 644-650.
35. 2 peripheral cannabinoid receptor. Biochim Biophys Acta 1307: 132-136.
36. 2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 101: 87-98.
37. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C et al. (2005). Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434: 782-786.
38. Ueda Y, Miyagawa N, Matsui T, Kaya T, Iwamura H (2005). Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Eur J Pharmacol 520: 164-171.
39. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL et al. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catelepsy. Neuropharmacology 48: 658-672.
40. 2 receptors. Science 310: 329-332.
41. 2-selective agonist, GW405833. Eur J Pharmacol 528: 65-72.
42. Woolfe G, MacDonald AD (1944). The evaluation of the analgesic action of pethidine. J Pharmacol Exp Ther 80: 300-307.
43. Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J (2005). Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135: 235-245.
44. Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK et al. (2006). In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB(2) receptor? Br J Pharmacol 149: 145-154.
45. Zimmermann M (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110.